This immuno-driven diagnostics company, known for partnerships with Genentech and Microsoft, just reported a notable insider ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for ...

In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...

Why Enveda, Faeth Therapeutics, Gilgamesh Pharma, and Argo Biopharma are among the most innovative companies in biotech right now. The Most Innovative Companies in biotech reflect a year in which ...

Headwinds in the sector are clearing. That is good news for venture firms seeking liquidity and for a stock market looking ...

One of the world’s largest biotech companies is closing its only office in the Bay Area. Pfizer is shutting down its office ...

Fees are Below Average compared to funds in the same category. Franklin Biotechnology Discovery Fund has an expense ratio of 1.01 percent. Risk is Above Average compared to funds in the same category ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said that ...

The news is the latest example of the biotech industry's struggles in the Bay Area.

The companies Earendil Labs, Teva Pharmaceuticals, and Solid Biosciences bagged the biggest biotech funding rounds overall in ...

Lipella Pharmaceuticals, a biotechnology company in Pittsburgh’s Homewood neighborhood, filed for bankruptcy protection ...